CETSA MS Profiling for a Comparative Assessment of FDA-Approved Antivirals Repurposed for COVID-19 Therapy Identifies TRIP13 as a Remdesivir Off-Target
Sign Up to like & getrecommendations! Published in 2020 at "Slas Discovery"
DOI: 10.1177/2472555220973597
Abstract: The reuse of preexisting small molecules for a novel emerging disease threat is a rapid measure to discover unknown applications for previously validated therapies. A pertinent and recent example where such a strategy could be… read more here.
Keywords: target; fda approved; cetsa; cetsa profiling ... See more keywords